Privia Health Group, Inc. PRVA
- Market cap
- $2.5B
- P/E
- 89.6×
Follow PRVA
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 20.20 | 17.99 | 19.68 | 15.92 | 18.77 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 50.77 | 44.64 | 30.15 | 24.05 | 26.51 |
High Price
|
|||
| — | — | — | — | 559 | 810 | 964 | 1,102 | 1,140 | 1,226 |
Employees
|
|||
| — | — | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 2 |
Revenue/Emp
|
|||
| — | — | 658 | 786 | 817 | 966 | 1,357 | 1,658 | 1,736 | 2,123 |
Revenue
|
|||
| — | — | 8.36% | 8.71% | 10.11% | 6.59% | 9.93% | 9.74% | 10.19% | 9.87% |
Gross Margin
|
|||
| — | — | (4) | 9 | 23 | (219) | (19) | 29 | 28 | 44 |
EBT
|
|||
| — | — | (0.61%) | 1.16% | 2.87% | (22.61%) | (1.37%) | 1.75% | 1.61% | 2.07% |
EBT Margin
|
|||
| — | 0 | (3) | 8 | 31 | (191) | (12) | 21 | 17 | 30 |
Net Income
|
|||
| — | — | 1 | 2 | 2 | 3 | 5 | 7 | 7 | 10 |
Depreciation
|
|||
| — | — | 6.21 | 8.20 | 8.52 | 9.39 | 12.26 | 14.20 | 14.54 | 17.38 |
Revenue/Sh
|
|||
| — | — | (0.03) | 0.08 | 0.32 | (1.83) | (0.08) | 0.20 | 0.12 | 0.19 |
Earnings/Sh
|
|||
| — | — | 0.05 | 0.25 | 0.41 | 0.53 | 0.43 | 0.69 | 0.92 | 1.34 |
Cash Flow/Sh
|
|||
| — | — | 0.00 | (0.06) | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | 0.05 | 0.19 | 0.40 | 0.53 | 0.43 | 0.69 | 0.92 | 1.34 |
Free CF/Sh
|
|||
| — | — | 0.00 | 0.00 | 1.50 | 4.37 | 4.69 | 5.20 | 5.72 | 6.47 |
Book Value/Sh
|
|||
| — | — | 106 | 96 | 96 | 103 | 111 | 117 | 119 | 122 |
Shares
|
|||
| — | — | 70.42 | 70.42 | 70.42 | 0.00 | 0.00 | 124.79 | 150.38 | 131.72 |
PE Ratio
|
|||
| — | — | 2.70 | 2.70 | 2.70 | 2.76 | 1.82 | 1.67 | 1.34 | 1.36 |
PS Ratio
|
|||
| — | — | 14.78 | 14.78 | 14.78 | 5.92 | 4.75 | 4.56 | 3.42 | 3.66 |
PB Ratio
|
|||
| — | — | 2.64 | 2.64 | 2.64 | 2.46 | 1.57 | 1.44 | 1.06 | 1.14 |
EV/Sales
|
|||
| — | — | 50.05 | 50.05 | 50.05 | 43.56 | 45.19 | 29.62 | 16.96 | 14.85 |
EV/FCF
|
|||
| — | — | 5 | 24 | 39 | 55 | 47 | 81 | 109 | 163 |
Op' Cash Flow
|
|||
| — | — | 0 | (6) | 0 | (1) | 0 | 0 | — | — |
Capex
|
|||
| — | — | 5 | 19 | 39 | 55 | 47 | 81 | 109 | 163 |
FCF
|
|||
| — | — | — | 14 | 43 | 256 | 288 | 314 | 386 | 342 |
Working Cap'
|
|||
| — | — | — | 40 | 33 | 32 | 8 | — | — | — |
Total Debt
|
|||
| — | — | — | (7) | (52) | (289) | (340) | (390) | (491) | (480) |
Net Debt
|
|||
| — | — | — | 0 | 144 | 450 | 519 | 607 | 683 | 791 |
Sh' Equity
|
|||
| — | — | 0.00% | 0.00% | 19.00% | (37.08%) | (1.16%) | 2.57% | 1.35% | 1.83% |
ROA
|
|||
| — | — | — | 0.00% | 17.28% | (84.26%) | (6.66%) | 5.92% | 5.52% | 6.87% |
ROIC
|
|||
| — | — | 0.00% | 6.42% | 24.61% | (63.39%) | (1.77%) | 4.10% | 2.23% | 3.11% |
ROE
|
|||
Privia Health Group, Inc. peers in Health Information Services
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SDGR Schrodinger, Inc. | $2.2B | 0.0× | Compare |
| OMCL Omnicell, Inc. | $1.5B | 39.5× | Compare |
| HTFL Heartflow, Inc. | $4.2B | 0.0× | Compare |
| CERT Certara, Inc. | $1.4B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DOCS Doximity, Inc. | $4.6B | 29.6× | Compare |
| WAY Waystar Holding Corp. | $4.7B | 34.3× | Compare |
| OMDA Omada Health, Inc. | $1.2B | 281× | Compare |
| GDRX GoodRx Holdings, Inc. | $1.2B | 62.5× | Compare |
Privia Health Group, Inc. (PRVA) key facts
- Privia Health Group, Inc. (PRVA) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024.
- Net income was $29.7 million, or $0.19 per share (basic), a net margin of 1.08%.
- As of September 25, 2026, PRVA traded at $19.71, a market capitalization of $2.5 billion.
- At that price the stock trades at 89.6× trailing-twelve-month earnings and 1.1× sales.
- Return on equity was 3.11% and debt-to-equity 0.00.
Privia Health Group, Inc. (PRVA) Latest News
19 Sep
Privia Health Group (PRVA) draws investor focus amid developments that may support its healthcare services growth and market positioning. Attention factors point to moderately noticeable effects on operations and sentiment but limited overall trajectory change.
20 Aug
Privia Health Group reported Q2 earnings, triggering analysis of whether investors should buy, sell or hold the stock amid evaluation of financial results and outlook. Q2 earnings results directly shape near-term valuation and investor positioning for Privia Health.
15 Aug
Privia Health Group's Q2 earnings call featured five top analyst questions focused on growth strategies, operational metrics, market expansion and financial outlook. Analyst questions from the earnings call highlight areas of investor focus that may moderately influence near-term market sentiment and performance expectations for Privia Health.
13 Aug
Privia Health raised its financial guidance yet again, prompting questions on whether the stock price adequately reflects the ongoing positive updates. Repeated guidance increases point to stronger financial performance that can lift near-term investor sentiment and valuation.
Privia Health Group reported Q2 2026 financial results and outlook during its earnings call. Quarterly earnings results and management commentary provide updates on financial performance and guidance with direct implications for valuation.
9 Aug
Privia Health Group Q2 revenue grew faster than profits with margin expansion remaining a priority focus. Q2 revenue growth exceeding profits points to ongoing profitability pressures that can moderately affect near-term market views.
Privia Health Group raised 2026 revenue guidance and expanded its footprint, but shares fell 5.2%. Raising long-term revenue guidance and footprint expansion can moderately lift future financial outlook and positioning.
7 Aug
Privia Health Group reported Q2 results in its earnings call, highlighting revenue growth, patient acquisition metrics, margin trends, and updated full-year guidance amid ongoing healthcare market expansion. Q2 earnings figures and guidance directly shape near-term valuation and investor positioning for the company.
6 Aug
Privia Health Group Inc (PRVA) reported strong growth in Q2 2026 earnings call and raised its financial outlook. Strong Q2 2026 growth and raised guidance signal major positive shifts in financial trajectory and market sentiment.
Privia Health (PRVA) Q2 earnings key metrics fell short of or beat consensus estimates in several areas including revenue and EPS. Q2 earnings metrics versus estimates can shift near-term investor sentiment on financial performance.
Privia Health exceeded Q2 CY2026 sales expectations. Q2 CY2026 sales beat raises near-term market sentiment but does not alter long-term trajectory.
Privia Health Group reports strong second quarter and year-to-date 2026 results. Strong quarterly results signal positive operational trends likely to influence near-term market sentiment.
5 Jun
Privia Health Group faces a shifting narrative amid mixed analyst targets alongside new deals that could reshape market perceptions. Mixed targets paired with new deals point to moderate influence on operations and sentiment without major trajectory shifts.
27 May
Privia Health expands into New Jersey market. New Jersey market entry broadens geographic footprint and growth opportunities.
14 May
Privia Health Group's (NASDAQ:PRVA) statutory profit understates its true earnings quality, as adjusted metrics reveal stronger underlying financial performance and healthier profitability. Adjusted earnings highlight better financial health, moderately boosting investor perception without transformative changes.
8 May
Privia Health Group released Q1 earnings call highlights, detailing financial performance, revenue growth, membership increases, and forward guidance amid healthcare market dynamics. Q1 earnings highlights cover financial results, operational metrics, and guidance that significantly shape investor expectations and stock trajectory.
Privia Health Group, Inc. Q1 2026 earnings call summary covers financial results, operational updates, and forward guidance for the healthcare management company. Quarterly earnings summaries directly reveal financial health, growth metrics, and strategic outlook, significantly influencing PRVA's stock performance and investor confidence.
7 May
Privia Health (PRVA) Q1 earnings key metrics compared to estimates, highlighting performance against analyst expectations. Q1 earnings metrics versus estimates can significantly sway investor sentiment and PRVA's stock trajectory.
Privia Health (NASDAQ:PRVA) reported better-than-expected sales for Q1 CY2026. Better-than-expected Q1 CY2026 sales boost investor sentiment and signal strong near-term growth for PRVA.
Privia Health Group, Inc. (PRVA) reported first quarter 2026 financial results. Quarterly earnings reports like Q1 2026 results typically drive significant shifts in stock price and long-term investor outlook for PRVA.
Privia Health (PRVA) missed Q1 earnings estimates. Missing Q1 earnings signals weaker financial performance, likely causing moderate short-term pressure on stock price and investor sentiment.
23 Apr
Privia Health (NASDAQ:PRVA) earns top marks in Q4 earnings for healthcare technology providers. Top Q4 earnings marks indicate strong financial performance driving positive investor sentiment and future trajectory.
30 Mar
Privia Health Group (PRVA)'s investment story is quietly shifting after Q4 results, signaling evolving narratives around growth, margins, and strategic positioning. Post-Q4 changes are reshaping PRVA's investment narrative with potential major effects on growth trajectory and investor sentiment.
11 Mar
Privia Health (PRVA) stock faces buy, sell, or hold debate following Q4 earnings release, with analysis weighing financial results, growth outlook, and market position. Q4 earnings outcomes directly shape investor sentiment and stock trajectory through explicit buy/sell/hold guidance.
8 Mar
Privia Health achieves gains in EHR-based cancer screening, spotlighting its value-based care strategy. EHR cancer screening gains bolster Privia Health's value-based care narrative, positioning it for significant growth in competitive healthcare dynamics.
28 Feb
Privia Health Group, Inc. (PRVA) acquires Evolent ACO to expand its value-based care scale. Acquisition of Evolent ACO represents a major strategic expansion in Privia Health's core value-based care operations, likely boosting growth and market position.
Privia Health Group (PRVA) stock surged 8.0% after raising 2026 revenue guidance and surpassing Q4 targets. Raising long-term revenue guidance and beating quarterly targets indicates strong growth momentum, significantly lifting stock price and investor outlook.
27 Feb
Privia Health Group shared Q4 earnings call highlights, covering financial results, revenue growth, profitability metrics, membership expansion, and optimistic 2024 guidance amid healthcare market challenges. Q4 earnings highlights disclose key financials, growth metrics, and forward guidance directly shaping investor sentiment and stock trajectory.
Wall Street analysts forecast Privia Health (PRVA) stock could surge 25.45%. Analyst consensus targets 25.45% upside for PRVA, moderately influencing investor sentiment and short-term performance.
26 Feb
Privia Health Group Inc (PRVA) reported strong provider growth, platform expansion, and robust financial performance in Q4 2025 earnings call highlights. Strong provider growth and financial results in Q4 2025 earnings call indicate major strategic progress likely to boost PRVA's market performance.